ALNY$157.994.25%-7.01
Nachbörslich: 159.99+2.00 +1.27%
Alnylam Pharmaceuticals Inc (ALNY)
Date: 2026-11-02 16:00O: 163.10H: 163.90L: 156.00C: 157.99Vol: 3.973M
Schlusskurs vom Vortag:
$165.00
Offen:
$163.10
24-Stunden-Volumen:
3,972,838
Relatives Volumen:
1.15
Marktkapitalisierung:
$21.16B
Einnahmen:
$4.29B
Nettoeinkommen (Verlust:
$577.22M
KGV:
37.54
EPS:
$4.21
Netto-Cashflow:
$641.34M
1W Leistung:
-30.60%
1M Leistung:
-28.09%
6M Leistung:
-46.64%
1Y Leistung:
-65.36%
1-Tages-Spanne:
$156.00$163.90
1-Wochen-Bereich:
$156.00$232.88
52-Wochen-Spanne:
$156.00$479.79
Alnylam Pharmaceuticals Inc Aktie (ALNY) Unternehmensprofil
Firmenname
Alnylam Pharmaceuticals IncSektor
HealthcareBranche
BiotechnologyTelefon
(617) 551-8200Adresse
675 WEST KENDALL STREET, CAMBRIDGE, MA, USAALNY vs. VRTX, REGN, MRNA, ARGX, ONC vergleichen
| Aktien | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|
ALNY Alnylam Pharmaceuticals Inc | $21.16B | $3.71B | $238.87M | $465.38M | $4.21 |
 VRTX Vertex Pharmaceuticals Inc | $140.94B | $12.59B | $4.41B | $3.80B | $16.87 |
 REGN Regeneron Pharmaceuticals Inc | $99.46B | $16.90B | $4.82B | $3.83B | $41.04 |
 MRNA Moderna Inc | $88.17B | $2.23B | -$3.15B | -$1.24B | -$8.15 |
 ARGX Argen X Se Adr | $55.03B | $4.16B | $1.29B | $734.26M | $19.58 |
 ONC Beone Medicines Ltd Adr | $40.86B | $6.13B | $655.71M | $1.33B | $4.48 |
Alnylam Pharmaceuticals Inc Aktie (ALNY) Hochstufungen & Herabstufungen
Finanzdaten der Alnylam Pharmaceuticals Inc-Aktie (ALNY)
Alnylam Pharmaceuticals Inc-Aktie (ALNY) Insiderhandel
- SUPRAN BRYANOct 02 '26EVP, CLO and Secretary
- Transaktion
- Sale
- Kosten
- $226.88
- #Aktien
- 1,758
- Wert ($)
- 398,855
- #Aktien Gesamt
- 12,807
- SUPRAN BRYANOct 02 '26Officer
- Transaktion
- Proposed Sale
- Kosten
- $226.88
- #Aktien
- 1,758
- Wert ($)
- 398,862
- #Aktien Gesamt
- 0
- PYOTT DAVID E IJun 01 '26Director
- Transaktion
- Sale
- Kosten
- $299.18
- #Aktien
- 3,830
- Wert ($)
- 1,145,853
- #Aktien Gesamt
- 1,582
- PYOTT DAVID E IJun 01 '26Director
- Transaktion
- Option Exercise
- Kosten
- $0.00
- #Aktien
- 3,830
- Wert ($)
- 0
- #Aktien Gesamt
- 5,412
- PYOTT DAVID E IJun 01 '26Director
- Transaktion
- Proposed Sale
- Kosten
- $299.51
- #Aktien
- 3,830
- Wert ($)
- 1,147,123
- #Aktien Gesamt
- 0
- SCHULMAN AMY WMay 13 '26Director
- Transaktion
- Option Exercise
- Kosten
- $70.20
- #Aktien
- 11,250
- Wert ($)
- 789,750
- #Aktien Gesamt
- 23,211
- McLaughlin MelissaApr 06 '26Chief Human Resources Officer
- Transaktion
- Sale
- Kosten
- $330.42
- #Aktien
- 2,286
- Wert ($)
- 755,329
- #Aktien Gesamt
- 9,443
- McLaughlin MelissaApr 06 '26Officer
- Transaktion
- Proposed Sale
- Kosten
- $320.10
- #Aktien
- 2,286
- Wert ($)
- 731,749
- #Aktien Gesamt
- 0
- McLaughlin MelissaApr 02 '26Chief Human Resources Officer
- Transaktion
- Sale
- Kosten
- $319.59
- #Aktien
- 1,624
- Wert ($)
- 519,014
- #Aktien Gesamt
- 11,729
- Garg PushkalMar 05 '26Officer
- Transaktion
- Proposed Sale
- Kosten
- $323.69
- #Aktien
- 2,404
- Wert ($)
- 778,151
- #Aktien Gesamt
- 0
Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten
Should You Buy The Dip In Alnylam Stock? - Trefis
09:39 AMEarnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resilience - Yahoo Finance
09:00 AMTruist Downgrades Alnylam Pharmaceuticals (ALNY) to Hold, Cuts P - GuruFocus
06:56 AMFDA Decision Watch: Regeneron And Roche’s Autoimmune Drugs, Capricor’s DMD Therapy In Spotlight - Yahoo Finance
05:36 AMForm 4 Alnylam Pharmaceuticals Inc For: 2 November By Investing.com - Investing.com Nigeria
05:07 AMAlnylam Pharmaceuticals, Inc. (ALNY) Stock forecasts - Yahoo Finance Singapore
Nov 01, 2026Alnylam Pharmaceuticals, Inc. (ALNY) RNAi Roundtable: Exon 1 Targeting With Brezosiran for Huntington's Disease - Slideshow (NASDAQ:ALNY) 2026-10-30 - Seeking Alpha
Oct 30, 2026Alnylam Pharmaceuticals, Inc. (ALNY) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canada
Oct 30, 2026Alnylam Pharmaceuticals' Fundamentals Remain Strong Despite Lower-End Guidance Expectations, UBS Says - Yahoo Finance
Oct 30, 2026Alnylam Pharma stock downgraded at Bernstein (ALNY:NASDAQ) - Seeking Alpha
Oct 30, 2026Oppenheimer Adjusts Price Target on Alnylam Pharmaceuticals to $320 From $350, Keeps Outperform Rating - Yahoo Finance
Oct 30, 2026Alnylam Pharmaceuticals, Inc. (ALNY) Seasonal returns chart - Yahoo Finance Singapore
Oct 29, 2026Alnylam Pharmaceuticals Inc (ALNY) (Q3 2026) Earnings Call Highlights: TTR Franchise Surges 59% ... - Yahoo Finance
Oct 29, 2026Alnylam Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary - Yahoo Finance
Oct 29, 2026Alnylam Pharma downgraded by Stifel with a new price target - Quantisnow
Oct 29, 2026Alnylam Pharmaceuticals, Inc. reports results for the quarter ended September 30 - Earnings Summary - TradingView
Oct 29, 2026Alnylam Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Period Progress - Alnylam
Oct 29, 2026Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top Estimates - Zacks Investment Research
Oct 29, 2026Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top Estimates - Yahoo Finance
Oct 29, 2026Alnylam: Q3 Earnings Snapshot - Yahoo Finance
Oct 29, 2026UBS cuts target for Alnylam Pharmaceuticals stock from USD 550.00 to USD 354.00 - ad-hoc-news.de
Oct 27, 2026Alnylam Reports Up to 83% Huntingtin Reduction, Eyes 2027 Pivotal Trial - TradingView
Oct 26, 2026Alnylam Reports Up to 83% Huntingtin Reduction, Eyes 2027 Pivotal Trial - Yahoo Finance
Oct 26, 2026Alnylam Reports Up to 83% Huntingtin Reduction, Eyes 2027 Pivotal Trial - TradingView
Oct 26, 2026Alnylam Pharmaceuticals, Inc.- RNAi Roundtable Transcript - GuruFocus
Oct 26, 2026Alnylam: Amvuttra Growth And Brezosiran Strengthen The Bull Case (NASDAQ:ALNY) - Seeking Alpha
Oct 26, 2026Analysts Estimate Krystal Biotech, Inc. (KRYS) to Report a Decline in Earnings: What to Look Out for - Zacks Investment Research
Oct 26, 2026Alnylam Pharmaceuticals Inc. Research & Ratings | ALNY - Barron's
Oct 25, 2026Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Hun - Alnylam
Oct 23, 2026Alnylam Lobbying Rises Amid Medicare Drug Pricing Debate - Legis1
Oct 23, 2026Alnylam Pharmaceuticals (ALNY) Reports Promising Phase 1b Results for Huntington's Disease Therapy - GuruFocus
Oct 23, 2026Alnylam Pharmaceuticals, Inc. Estimates – NASDAQ:ALNY - TradingView
Oct 23, 2026Alnylam Pharmaceuticals (ALNY) Reports Promising Phase 1b Data f - GuruFocus
Oct 23, 2026Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight - GlobeNewswire Inc.
Oct 22, 2026Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Zacks Investment Research
Oct 22, 2026Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
Oct 22, 2026Alnylam Pharmaceuticals (ALNY) Cuts 2026 Guidance After AMVUTTRA Sales Beat, Is It Fully Valued - Simply Wall Street
Oct 22, 2026Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech? - Yahoo Finance
Oct 21, 2026Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech? - The Motley Fool
Oct 21, 2026Alnylam (ALNY): Can the RNAi Franchise Get it an Entry into the S&P 500 Index? - Yahoo Finance
Oct 20, 2026Alnylam to Present New Data Reinforcing Strength in RNAi-Powered - The National Law Review
Oct 19, 2026ALNYLAM PHARMACEUTICALS INC (ALNY.MX) Q4 FY2025 earnings call transcript - Yahoo Finance
Oct 18, 2026What Has Changed For Alnylam Pharmaceuticals Since Its 52% Fall - Simply Wall Street
Oct 17, 2026Alnylam Pharmaceuticals, Inc. (ALNY) Stock Forecasts - Yahoo Finance
Oct 16, 2026Alnylam Pharmaceuticals (NASDAQ:ALNY): Affordable Growth With RNAi Commercial Momentum - ChartMill
Oct 16, 2026Alnylam Pharmaceuticals, Inc. (ALNY) options chain - Yahoo Finance Australia
Oct 16, 2026UBS Adjusts Alnylam Pharmaceuticals Price Target to $354 From $550, Maintains Buy Rating - Yahoo Finance
Oct 15, 2026Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results - Alnylam
Oct 15, 2026
Oct 14, 2026
